New combo aims to revive immunotherapy in resistant cancers

NCT ID NCT07404332

Recruiting now Disease control Sponsor: Mohammed Milhem Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to find the safest dose and check for early signs of tumor shrinkage. The goal is to see if this approach can overcome resistance to immunotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 5-Azacitidine (a chemotherapy drug) combined with a PD-1/PD-L1 inhibitor (pembrolizumab, nivolumab, or cemiplimab)
What this could lead to: If it works, this could point toward a new treatment option for patients whose tumors no longer respond to standard immunotherapy.
What could go wrong: This is a very early Phase I trial with only 35 participants, so it is primarily testing safety and dosing. It is too soon to know if the combination will be effective, and there may be side effects from adding chemotherapy to immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED SOLID TUMOR METASTATIC TUMOR SOLID TUMOR

Contacts and locations

Locations

University of Iowa Health Care
RECRUITING

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.